Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use and perceived utility of [18 F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022.
Ambrosini V, Caplin M, Castaño JP, Christ E, Denecke T, Deroose CM, Dromain C, Falconi M, Grozinsky-Glasberg S, Hicks RJ, Hofland J, Kjaer A, Knigge UP, Kos-Kudla B, Koumarianou A, Krishna B, Lamarca A, Pavel M, Reed NS, Scarpa A, Srirajaskanthan R, Sundin A, Toumpanakis C, Prasad V. Ambrosini V, et al. Among authors: lamarca a. J Neuroendocrinol. 2024 Jan;36(1):e13359. doi: 10.1111/jne.13359. Epub 2023 Dec 14. J Neuroendocrinol. 2024. PMID: 38097193
Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, Carvhalo L, Franca Bezerra RO, Borg P, Vietti Violi N, Vidal Trueba H, de Mestier L, Schaefer N, Sundin A, Costa F, Pavel M, Dromain C; Knowledge Network. Lamarca A, et al. Oncologist. 2019 Nov;24(11):e1082-e1090. doi: 10.1634/theoncologist.2018-0672. Epub 2019 Mar 25. Oncologist. 2019. PMID: 30910869 Free PMC article.
Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study.
Lamarca A, Ronot M, Moalla S, Crona J, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, Carvhalo L, Bezerra ROF, Borg P, Vietti Violi N, Vidal Trueba H, de Mestier L, Scaefer N, Baudin E, Sundin A, Costa F, Pavel M, Dromain C. Lamarca A, et al. Clin Cancer Res. 2019 Nov 15;25(22):6692-6699. doi: 10.1158/1078-0432.CCR-19-0963. Epub 2019 Aug 2. Clin Cancer Res. 2019. PMID: 31375514
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
Prasad V, Srirajaskanthan R, Toumpanakis C, Grana CM, Baldari S, Shah T, Lamarca A, Courbon F, Scheidhauer K, Baudin E, Truong Thanh XM, Houchard A, Dromain C, Bodei L. Prasad V, et al. Among authors: lamarca a. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2358-2371. doi: 10.1007/s00259-020-04712-2. Epub 2020 Feb 15. Eur J Nucl Med Mol Imaging. 2020. PMID: 32062681 Free PMC article.
Safety, tolerability and clinical implementation of 'ready-to-use' 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
Manoharan P, Lamarca A, Navalkissoor S, Calero J, Chan PS, Julyan P, Sierra M, Caplin M, Valle J. Manoharan P, et al. Among authors: lamarca a. ESMO Open. 2020 Mar;5(2):e000650. doi: 10.1136/esmoopen-2019-000650. ESMO Open. 2020. PMID: 32188715 Free PMC article. Clinical Trial.
Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability.
Dromain C, Sundin A, Najran P, Vidal Trueba H, Dioguardi Burgio M, Crona J, Opalinska M, Carvalho L, Franca R, Borg P, Vietti Violi N, Schaefer N, Lopez C, Pezzutti D, de Mestier L, Lamarca A, Costa F, Pavel M, Ronot M. Dromain C, et al. Among authors: lamarca a. Neuroendocrinology. 2021;111(9):831-839. doi: 10.1159/000510445. Epub 2020 Jul 27. Neuroendocrinology. 2021. PMID: 32717738
255 results